Ticci Chiara, Orsucci Daniele, Ardissone Anna, Bello Luca, Bertini Enrico, Bonato Irene, Bruno Claudio, Carelli Valerio, Diodato Daria, Doccini Stefano, Donati Maria Alice, Dosi Claudia, Filosto Massimiliano, Fiorillo Chiara, La Morgia Chiara, Lamperti Costanza, Marchet Silvia, Martinelli Diego, Minetti Carlo, Moggio Maurizio, Mongini Tiziana Enrica, Montano Vincenzo, Moroni Isabella, Musumeci Olimpia, Pancheri Elia, Pegoraro Elena, Primiano Guido, Procopio Elena, Rubegni Anna, Scalise Roberta, Sciacco Monica, Servidei Serenella, Siciliano Gabriele, Simoncini Costanza, Tolomeo Deborah, Tonin Paola, Toscano Antonio, Tubili Flavia, Mancuso Michelangelo, Battini Roberta, Santorelli Filippo Maria
IRCCS Fondazione Stella Maris, 56018 Pisa, Italy.
Unit of Neurology, San Luca Hospital, 55100 Lucca, Italy.
J Clin Med. 2021 May 12;10(10):2063. doi: 10.3390/jcm10102063.
Movement disorders are increasingly being recognized as a manifestation of childhood-onset mitochondrial diseases (MDs). However, the spectrum and characteristics of these conditions have not been studied in detail in the context of a well-defined cohort of patients. We retrospectively explored a cohort of individuals with childhood-onset MDs querying the Nationwide Italian Collaborative Network of Mitochondrial Diseases database. Using a customized online questionnaire, we attempted to collect data from the subgroup of patients with movement disorders. Complete information was available for 102 patients. Movement disorder was the presenting feature of MD in 45 individuals, with a mean age at onset of 11 years. Ataxia was the most common movement disorder at onset, followed by dystonia, tremor, hypokinetic disorders, chorea, and myoclonus. During the disease course, most patients (67.7%) encountered a worsening of their movement disorder. Basal ganglia involvement, cerebral white matter changes, and cerebellar atrophy were the most commonly associated neuroradiological patterns. Forty-one patients harbored point mutations in the mitochondrial DNA, 10 carried mitochondrial DNA rearrangements, and 41 cases presented mutations in nuclear-DNA-encoded genes, the latter being associated with an earlier onset and a higher impairment in activities of daily living. Among our patients, 32 individuals received pharmacological treatment; clonazepam and oral baclofen were the most commonly used drugs, whereas levodopa and intrathecal baclofen administration were the most effective. A better delineation of the movement disorders phenotypes starting in childhood may improve our diagnostic workup in MDs, fine tuning management, and treatment of affected patients.
运动障碍越来越被认为是儿童期起病的线粒体疾病(MDs)的一种表现。然而,在一个明确界定的患者队列背景下,这些疾病的范围和特征尚未得到详细研究。我们回顾性地探究了一组儿童期起病的MDs患者,查询了意大利全国线粒体疾病协作网络数据库。通过使用定制的在线问卷,我们试图从患有运动障碍的患者亚组中收集数据。102例患者有完整信息。45例患者中运动障碍是MD的首发特征,发病时平均年龄为11岁。共济失调是最常见的首发运动障碍,其次是肌张力障碍、震颤、运动减少性障碍、舞蹈症和肌阵挛。在疾病过程中,大多数患者(67.7%)的运动障碍病情加重。基底节受累、脑白质改变和小脑萎缩是最常见的相关神经影像学表现。41例患者线粒体DNA存在点突变,10例存在线粒体DNA重排,41例患者核DNA编码基因存在突变,后者与发病较早和日常生活活动能力受损程度较高有关。在我们的患者中,32例接受了药物治疗;氯硝西泮和口服巴氯芬是最常用的药物,而左旋多巴和鞘内注射巴氯芬最为有效。更好地描述儿童期起病的运动障碍表型可能会改善我们对MDs的诊断检查、优化对受影响患者的管理和治疗。